Table 1.
Expression of Hippo pathway–associated genes in Pals1-deficient kidneys compared with the littermate controls
| Gene | Name | Signaling Pathway | Six Cre2- versus Six2-Cre+ | |
|---|---|---|---|---|
| Fold Change | P Value | |||
| Myc | myelocytomatosis oncogene | Hippo | 3.94 | 1.31E-04 |
| Ctgf | connective tissue growth factor | Hippo | 2.52 | 4.01E-04 |
| Cyr61 | cysteine rich protein 61 | Hippo | 2.48 | 5.28E-03 |
| Axl | AXL receptor tyrosine kinase | Hippo | 2.04 | 6.85E-03 |
| Birc2 | baculoviral IAP repeat-containing 2 | Hippo | 1.87 | 3.86E-03 |
| Runx2 | Runt-related transcription factor 2 | Hippo | 1.54 | 9.33E-03 |
| Sox4 | SRY (sex-determining region Y)-box 4 | Hippo | 2.33 | 6.34E-05 |
| Tead1 | TEA domain family member 1 | Hippo | 1.59 | 9.94E-04 |
| Serpine1 | Serine/cysteine peptidase inhibitor, clade E, member 1 (Pai-1) | Hippo/TGF-β | 8.60 | 3.56E-04 |
| Runx1 | Runt-related transcription factor 1 | Hippo/TGF-β | 4.72 | 1.95E-04 |
| Cdkn1a | cyclin-dependent kinase inhibitor 1A | Hippo/TGF-β | 2.98 | 6.59E-05 |
| Col1a1 | collagen, type I, alpha 1 | Hippo/TGF-β | 2.81 | 6.20E-03 |
| Tgfbi | TGF, β induced | Hippo/TGF-β | 2.61 | 3.55E-03 |
| Col1a2 | collagen, type I, α 2 | Hippo/TGF-β | 2.47 | 7.88E-03 |
| Tgfb1 | TGF, β 1 | Hippo/TGF-β | 2.20 | 3.59E-03 |
| Fos | FBJ osteosarcoma oncogene | Hippo/TGF-β | 2.04 | 1.25E-02 |
| Junb | jun B proto-oncogene | Hippo/TGF-β | 2.30 | 2.34E-05 |
| Thbs1 | thrombospondin 1 | Hippo/TGF-β | 2.06 | 1.17E-02 |
| Tgfb3 | TGF, β 3 | Hippo/TGF-β | 1.90 | 2.96E-02 |
| Tsc22d1 | TSC22 domain family, member 1 | Hippo/TGF-β | 1.78 | 2.60E-03 |
| Dcn | decorin | Hippo/TGF-β | 1.92 | 2.86E-02 |
| Ifrd1 | IFN-related developmental regulator 1 | Hippo/TGF-β | 1.63 | 3.29E-03 |
Target genes of the Hippo signaling pathway and of genes that are affected by crosstalk between the Hippo and Wnt or Hippo and TGF-β are differentially regulated in Six2-Cre+ kidneys. The table lists a selection of genes that are significantly (see P value) upregulated in Pals1-deficient kidneys (Six2-Cre+) and are given in fold-change compared with the littermate controls (Six2-Cre−). Details of the microarray analysis are summarized in the Supplemental Material.